-

SynergenX Opens Testosterone Cypionate Therapy to Female Patients

HOUSTON--(BUSINESS WIRE)--SynergenX, national leader in customized hormone optimization, prescription weight loss, and medically supervised wellness, is expanding its hormone replacement therapy (HRT) services for women to include injections of testosterone cypionate. Beginning July 28, 2025, these services will be available at all locations nationwide.

SynergenX Opens Testosterone Cypionate Therapy to Female Patients

Share

This expansion marks the first time that female patients can access the custom-dosed testosterone cypionate injections available to male patients, enabling them to experience the benefits of injection-based testosterone therapy.

Testosterone Injections for Women

  • An Expansion of Women’s HRT – Female patients at SynergenX have long been able to receive estrogen, progesterone, and testosterone therapies in the forms of pellets and creams. Now, female patients have access to the same custom-dosed testosterone care that their male counterparts do.
  • Two paths for Testosterone Injections – Female patients will be able to choose from in-office injections or they may take part in the Self-Inject TRT program, allowing them to receive pre-filled syringes of testosterone delivered directly to their residences. Each path is guided by providers and informed by comprehensive lab analysis.
  • Comprehensive Medical Onboarding – Female patients can begin treatment after an in-depth medical evaluation that includes an Autonomic Nervous System (ANS) test, metabolic panel, and a comprehensive hormone panel. Unlike male patients, women may begin therapy immediately upon presenting at least one qualifying symptom and receiving provider confirmation.

Raising the Standard in Women’s Hormone Health

Hormonal imbalances in women are often overlooked or treated with generic solutions. Developed in response to widespread clinical need, this program combines laboratory-grade diagnostics, expert clinical oversight, and flexible treatment delivery models, creating a new standard of care that prioritizes efficacy, safety, and long-term results.

“Testosterone cypionate injections are the gold standard of testosterone therapy, and I’m proud that our female patients can now have access to this life-changing treatment,” said Wayne Wilson, Founder and CEO of SynergenX. “At SynergenX we are committed to helping patients improve their lives through medically supervised hormone therapy, tailored to each individual according to need.”

About SynergenX

Headquartered in Houston, TX, SynergenX is an award-winning network of hormone health and wellness clinics serving Texas and Illinois. Lauded for its commitment to the highest clinical standards and custom-dosed hormone therapies, SynergenX is a front-runner in provider-led hormone therapy, weight loss, and wellness.

Contacts

Media Contact:
Jordan Bailey
Marketing Communications Specialist, SynergenX / Low T Center
8326391569
jbailey@synergenxhealth.com

SynergenX


Release Versions

Contacts

Media Contact:
Jordan Bailey
Marketing Communications Specialist, SynergenX / Low T Center
8326391569
jbailey@synergenxhealth.com

Social Media Profiles
More News From SynergenX

SynergenX Network Clinics Expand Peptide Therapy Options with BPC-157 and CJC-1295 + Ipamorelin

HOUSTON--(BUSINESS WIRE)--SynergenX, veteran-owned leader in personalized hormone and wellness medicine, is expanding its peptide therapy program with the addition of BPC-157 and CJC-1295 + Ipamorelin, two popular new peptide therapies that allow patients to pursue natural, rejuvenating option for health optimization, alone or in addition to hormone and weight-loss therapies. Beginning October 6, 2025, patients across SynergenX, Low T Center, and HerKare locations will have access to these adva...

Low T Center Launches Women’s Hormone Health Services Nationwide

HOUSTON--(BUSINESS WIRE)--Low T Center, leader in personalized hormone optimization, is expanding its hormone care services to include women’s hormone replacement therapy (HRT), including in-clinic and self-inject testosterone replacement therapy. Beginning July 28, 2025, these services will be available at all clinic locations nationwide. This expansion advances the accessibility of hormone care for women, reflecting a continued investment in precision medicine, clinical oversight, and individ...
Back to Newsroom